Verge Healthtech Fund

VC Singapore, Singapore · Founded 2018

Website

Verge HealthTech Fund focuses exclusively on early-stage, impactful health technology startups globally that address healthcare access, quality, and affordability. The fund actively avoids biotech and asset-heavy infrastructure, prioritizing scalable deeptech, smart medical devices, next-gen diagnostics, digital therapeutics, and healthcare SaaS.

About Verge Healthtech Fund

Verge Healthtech Fund is a Singapore-based early-stage healthtech specialist at verge.fund with a Singapore LinkedIn presence and active Crunchbase profile, focused on emerging-market healthtech innovation across Asia, Africa, and Latin America. While the input fields are unfilled, Verge is publicly understood as a seed-stage investor explicitly oriented to global health and emerging market healthcare access, with a portfolio spanning telemedicine, diagnostics, primary care delivery, and digital health infrastructure in low- and middle-income countries. For healthcare AI founders, Verge is a strong candidate if your company directly addresses emerging market healthcare access challenges with AI-native products: clinical decision support for resource-constrained settings, AI-assisted diagnostics for low-cost devices, language-localized telemedicine, frontline health worker tools, and pharmacy or supply chain automation. Pure US or European clinical software founders should look elsewhere; Verge’s thesis explicitly excludes high-income market focus. Check sizes for the firm typically span USD 250K to USD 1M at seed with selective follow-on. Geographic preference is Asia, Africa, and Latin America with operational presence or commercial traction in those markets. Best entry path is a warm introduction through the global health funding community, the World Bank or Gates Foundation network, or an existing Verge portfolio founder, supplemented by a LinkedIn message to the managing partner with a clear emerging-market thesis and traction evidence. Founders should bring concrete pilot data from target markets, not generalized global health TAM slides; this firm rewards specificity and operating reality over narrative.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.

Share your experience

At a glance

Type VC

Stages Seed, Series A

Check size $250k-$1M

Sub-verticals AI/ML in Healthcare, Diagnostics, Digital Health

HQ Singapore, Singapore

Founded 2018

Visit website

Healthcare AI tools backed by Verge Healthtech Fund

Tools made by companies in Verge Healthtech Fund's portfolio that we cover in the directory.

Neosoma Brain Mets

Neosoma

Neurology AI

Neosoma Brain Mets is an FDA-cleared AI-powered software for rapid MRI assessment and auto-contouring of brain metastases, providing near-real-time insights for multidisciplinary neuro-oncology teams.

Contact for details; priced based on mri volume.

NS-HGlio

Neosoma

Neurology AI

Neosoma offers an FDA-cleared AI-based software platform, NS-HGlio, for semi-automatic labeling, visualization, and volumetric quantification of high-grade brain gliomas from standard MRI images, aiding in treatment planning and longitudinal assessment.

Priced based on mri volume

AISight Dx

PathAI

Pathology AI

AISight Dx is PathAI's FDA-cleared, cloud-native digital pathology image management system that integrates AI algorithms to support laboratory workflows, clinical operations, and primary diagnosis in the US. It streamlines diagnostic workflows, enables precision collaboration, and supports accurate, efficient diagnoses across various settings.

Contact for quote

Neosoma Platform

Neosoma

Clinical Decision Support & Reference

The Neosoma Platform is a cloud-based, FDA-cleared AI tool for neuro-oncology, providing automated tumor mapping, lesion tracking, and real-time insights for brain metastases and gliomas.

Volume-based